GlassScriptPhysician profile
Anna C Reid
NPI 1215580600
$3,513.33
in general payments reported to CMS, 2019-2025
27 companies · $1,206 in 2025
The $1,206 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $165 · 2023: $1,064 · 2024: $1,078 · 2025: $1,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,348.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $799.92 | 2023-2025 | Lifevest |
| Pfizer INC. | $453.77 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.68 | 2022-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $226.35 | 2023-2025 | Camzyos, Eliquis |
| Amgen INC. | $183.22 | 2023-2025 | Repatha, Repatha |
| Inspire Medical Systems, INC. | $173.30 | 2023 | Inspire |
| Alnylam Pharmaceuticals INC. | $161.73 | 2023-2025 | Onpattro |
| Impulse Dynamics (USA) INC. | $157.15 | 2023 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $129.27 | 2023-2025 | Farxiga |
| Boston Scientific Corporation | $123.07 | 2023-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $118.37 | 2022-2025 | |
| Medtronic, INC. | $109.31 | 2025 | Symplicity G3 |
| Tactile Systems Technology INC | $88.24 | 2022-2024 | Entre Plus, Flexitouch Plus |
| Abiomed | $77.36 | 2024 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $60.97 | 2024 | Arcalyst |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $50.87 | 2023 | Inpefa |
| Merck Sharp & Dohme LLC | $43.53 | 2023-2024 | Verquvo |
| Edwards Lifesciences Corporation | $39.18 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Actelion Pharmaceuticals US, INC. | $37.74 | 2022 | |
| Scpharmaceuticals INC. | $36.29 | 2024 | |
| Becton, Dickinson and Company | $33.22 | 2024 | |
| Biotronik INC. | $33.11 | 2025 | Amvia Edge |
| Glaxosmithkline, LLC. | $20.17 | 2025 | Arexvy, Shingrix |
| Atricure, INC. | $19.64 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.26 | 2024 | |
| Vivaquant INC, Dba Rhythm Express | $16.00 | 2025 | Rhythm Express |
| Amarin Pharma, INC. | $14.61 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.